Journals / Çocuk Acil ve Yoğun Bakım Dergisi / 2015 / Cilt: 2 - Sayı: 1

A Baby Developing Digoxin Poisoning in Pediatric Intensive Care Unit: A Case Report

Çocuk Yoğun Bakım Servisinde İzlenen Bir Bebekte Gelişen Digoksin Zehirlenmesi:Olgu Sunumu

Pages
35–39
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In summary, we aimed to point out that digoxin toxicity might occur even in therapeutic dose ranges in critically ill patients leading to AV block.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Digoxin is one of the most frequently used positive inotropic agents.
📊
Key Findings & Data:A 3 month-old girl with esophageal atresia and tracheoesophageal fistula developed heart failure due to ventricular septal defect, and was admitted to pediatric intensive care unit.
💡
Conclusion & Impact:In summary, we aimed to point out that digoxin toxicity might occur even in therapeutic dose ranges in critically ill patients leading to AV block.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Digoxin is one of the most frequently used positive inotropic agents. Dig xin toxicity can easily develop due to the narrow therapeutic dose range. In this case report, we aimed to emphasize that digoxin poisoning may come out more easily in critical patients. A 3 month-old girl with esophageal atresia and tracheoesophageal fistula developed heart failure due to ventricular septal defect, and was admitted to pediatric intensive care unit. Appropriate maintenance dose of oral digoxin treatment without a loading dose was started in addition to dopamine, dobutamine and furosemide. However, atrioventricular (AV) block was observed due to digoxin intoxication. In summary, we aimed to point out that digoxin toxicity might occur even in therapeutic dose ranges in critically ill patients leading to AV block.

Özet

Digoksin en sık kullanılan pozitif inot ropik ajanlardan bi ri dir. Te da vi edi ci doz ara lığının dar ol ma sın dan do la yı di gok sin ze hir lenmesi ko lay lık la ge li şe bil mekte dir. Bu olgu sunumun da kri tik has talarda di gok sin ze hir lenmesi nin da ha ko lay ge - li şe bi le ce ği nin vur gulanma sı amaç lanmıştır. Özofagus at rezi si, tra ke oö zofagi yal fistül, ventriküler septal defekt tanıla rıy la iz le nen 3 aylık kız olgu kalp yetmez li ği ne - deniy le çocuk yoğun bakım servisine alın mış tır. Do pa min, do buta min ve fu ro se mid te da vi le ri baş la nan ol gu nun iz leminde yük le me dozu ya pıl ma dan uygun idame dozda oral di gok sin damla başlanmıştır. Ancak ol gu da di gok sin ze hir lenmesi ne bağlı at ri oventriküler (AV) tam blok ge lişmiştir. Sonuç olarak digoksin zehirlenmesi kritik hastalarda tedavi dozunda da görülebilmekte ve AV bloğa neden olabilmektedir. CAYD 2015;2(1):35-40.

🔖

Cite This Article

ANIL, A. B., KARADAŞ, U., KÖSE, E., DOĞAN, M. A., KANIK, M. A., ANIL, M. (2015). A Baby Developing Digoxin Poisoning in Pediatric Intensive Care Unit: A Case Report. Çocuk Acil ve Yoğun Bakım Dergisi, Cilt: 2 - Sayı: 1, 35–39. https://ajindex.com/articles/162322

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Art man M. Phar ma co lo gic The rapy. In: Al len HP, Clark EB, Gut ge sell HP, Dris coll DS, eds. Moss and Adams' He art di - sea ses in in fants, chil dren, and ado les cents, Inc lu ding the fe tus and Yo ung Adult, 6th edn. Phi le delp hi a, Lip pin cott Wil li ams & Wil kins, 2001: 335-6.
  2. Te ke to mo CK, Hod ding JH, Kra us DM. Le xi-Comp's Pe di - at ric Phar ma co logy Com pa ni on Gui de, 12th edi ti on, Le xi- Comp Inc, Chi ca go, 2005: 419-20. Smith TW. Di gi ta lis: Mec ha nisms of ac ti on and cli ni cal use. N Engl J Med 1998; 318:358-65.
  3. Hak lin H, Ra domsky M, Blie den L, Frand M, Mill man P, Bo - ic his H. Ste ady sta te se rum di go xin con cen tra ti on in re la - ti on to di gi ta lis to xi city in ne ona tes and in fants. Pe di at rics, 1978; 61:184-8. Soy ka LF. Cli ni cal Phar ma co logy of Di gok sin. Pe di atr Clin North Am 1972; 19:241-56.
  4. Tun cok Y, Ha zan E, Oto O, Gu ven H, Ca tal yu rek H, Kal - kan S. Re la ti ons hip bet we en high se rum di go xin le vels and to xi city. Int J Clin Phar ma col Ther 1997; 35:366-8.
  5. Wells TG, Yo ung RA, Ke arns GL. Age re la ted dif fe ren ces in di gok sin to xi city and its tre at ment. Drug Saf, 1992; 7:135- 51. Cam bo ni e G, an Ha ack K, Gu yon G, Badr M, Fo ur ni er-Fav - re S, So uk si I, Gu il lau mont S. Di gi ta lis in to xi ca ti on du ring the ne ona tal pe ri od: ro le of dehy dra ti on. Arch Pe di atr, 2000; 7:633- 6. Wang M-T, Sun C-Y, Chan ALF, Li an P-W, Le u H-B, Hsu Y- J. Risk of di go xin in to xi ca ti on in he art fa ilu re pa ti ents ex - po sed to di go xin-di ure tic in te rac ti ons: a po pu la ti on-ba sed study. Br J Clin Phar ma col 2010;70(2):258-67.
  6. Ha sim O, Meh met K, Na ci C. Di go xin To xi city In Child ho - od: Re port of 12 Ca ses. J.Curr Pe di atr 2007; 5:87-91.
  7. Çı tak A, Yıl maz HL. Pe di at rik Ze hir len me ler, 1. bas kı, İs - tan bul Tıp Ki ta be vi, İs tan bul, 2011;141-8.
  8. Git tel man MA, Step han M, Perry H. Acu te pe di at ric di go - xin in ges ti on. Pe di atr Emerg Ca re 1999; 15:359-62.
  9. Ma G, Brady WJ, Pol lack M, Chan TC. Elec tro car di og rap - hic ma ni fes ta ti ons: di gi ta lis to xi city. J Emerg Med 2001; 20:145-52.
  10. Lau rent G, Pou let B, Fal con-Eic her S, Pe tit A, Bal lo ut J, Io - ves cu D, Gou yon JB, Lou is P. An ti-di go xin an ti bo di es in se - ve re di gi ta lis po iso ning in an 11-day old in fant. Re vi ew of li te ra tu re. Ann Car di ol An gei ol (Pa ris), 2001; 50:274-84.
  11. Husby P, Fars tad M, Brock-Ut ne JG, Kol ler ME